Alnylam Pharmaceuticals Inc
$ 308.48
-4.28%
12 Feb - close price
- Market Cap 40,754,471,000 USD
- Current Price $ 308.48
- High / Low $ 315.51 / 298.00
- Stock P/E 131.83
- Book Value 1.77
- EPS 2.34
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.33 %
- 52 Week High 495.55
- 52 Week Low 205.87
About
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$477.58
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 1.25 | 2.9 | -0.51 | -0.01 | 0.06 | -0.5 | -0.13 | -0.52 | -1.1 | 1.15 | -2.21 | -1.4 |
| Estimated EPS | 1.24 | 1.44 | -0.7 | -0.37 | -0.14 | -0.39 | -1.08 | -1.18 | -1.32 | -1.34 | -1.37 | -1.77 |
| Surprise | 0.01 | 1.46 | 0.19 | 0.36 | 0.2 | -0.11 | 0.95 | 0.66 | 0.22 | 2.49 | -0.84 | 0.37 |
| Surprise Percentage | 0.8065% | 101.3889% | 27.1429% | 97.2973% | 142.8571% | -28.2051% | 87.963% | 55.9322% | 16.6667% | 185.8209% | -61.3139% | 20.904% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALNY
2026-02-12 21:57:50
Alnylam Pharmaceutical is projecting a 25% compound annual growth rate (CAGR) for its revenue through 2030, driven by the strong launch of its drug AMVUTTRA and the expansion of its clinical pipeline. The company is focusing on leveraging its RNAi therapeutics platform to introduce new treatments and expand its market presence, aiming for significant financial growth in the coming years.
2026-02-12 20:57:50
Alnylam Pharmaceuticals (ALNY) reported a significant swing to profit in Q4 and full year 2025, with revenues sharply increasing. Despite strong earnings, the stock has seen declines recently, leading to questions about its current valuation. The company is considered 34.5% undervalued by one narrative, largely due to the robust performance of its drug AMVUTTRA, though a sales-based pricing view suggests its market pricing looks richer compared to industry peers.
2026-02-12 19:28:08
Needham & Company LLC reduced its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $529 to $510, while maintaining a "buy" rating, following an earnings and revenue miss. The biopharmaceutical company reported an EPS of $0.82 against an expected $1.43 and revenue of $1.10 billion versus an anticipated $1.16 billion. Despite an 84.9% year-over-year revenue increase, the stock fell, and the article notes recent insider selling by executives.
2026-02-12 14:57:50
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q4 2025 earnings, exceeding EPS expectations with $1.25 against a forecast of $1.19, but missed revenue projections by reporting $1.1 billion against an anticipated $1.15 billion. Despite the revenue miss, the company's full-year net product revenues grew 81% to nearly $3 billion, driven by the strong performance of AMVUTTRA. Alnylam projects 71% growth in 2026 net product revenue and aims for a 25% revenue compound annual growth rate through 2030, with plans to expand its RNAi delivery and clinical programs.
2026-02-12 13:30:00
ALNYLAM PHARMACEUTICALS ($ALNY) released its Q4 2025 earnings, reporting $1.25 per share, which beat estimates, but revenue of $1.097 billion missed expectations. Insider trading activity showed significant sales by executives and board members, while institutional holdings saw both additions and reductions by major firms. Analysts generally maintain "Buy" or "Overweight" ratings for the stock, with a median price target of $509.0.
2026-02-12 12:57:50
Krilogy Financial LLC recently acquired a new position of 3,822 shares, valued at approximately $1.66 million, in Alnylam Pharmaceuticals, Inc. during the third quarter. This comes as institutional ownership in Alnylam stands at 92.97%, despite notable insider selling totaling over $12 million in the last 90 days. Analysts maintain a "Moderate Buy" consensus rating for ALNY with an average target price of $477.13, significantly higher than its current trading price of around $321.99.
